Abstract
Background
The promoter region is a key element of gene expression regulation. In mammals, most of the genes present, at the level of their promoter, a large number of islands CpG. Age also is seen as another factor for developing breast cell cancer reaching the tumour stage.
Aim
This study aimed to explore the hypermethylation of the BRCA1/2 promoter gene in women breast cancer and correlation with age and tumour stage.
Materials and methods
Fifty biopsies were derived from Moroccan women treated for breast carcinoma, the DNA extracted was treated by bisulphite and the targeted BRCA1/2 Amplicons were amplified by specific methylation primers (MSP).
Results
The result shows that 62% of the samples were BRCA1 methylated in addition and negative result for BRCA2, these positive epigenetic factor were remarkable in women over 47 years and at the stage of malignant tumour.
Conclusion
These results show that half of the methylated samples are positive with a majority of over 47 years old, and confirms that age might be an additional factor for breast cancer development.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The project respects the agreement of the ethics committee (No. 3/2018/30 April/2018-Morocco).
Abbreviations
- BRCA1 :
-
Breast cancer 1
- BRCA2 :
-
Breast cancer 2
- CpG :
-
Cytosine-phosphate-guanine
- DNA :
-
Disoxyribonucleotide
- CGI :
-
Cytosine-guanine island
- Bp :
-
Base pairs
References
Zhang TY, Keown CL, Wen X, Li J, Vousden DA, Anacker C, Meaney MJ (2018) Environmental enrichment increases transcriptional and epigenetic differentiation between mouse dorsal and ventral dentate gyrus. Nat commun 9(1):1–11. https://doi.org/10.1038/s41467-017-02748-x
Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321(6067):209–213
Gao J, Cahill CM, Huang X, Roffman JL, Lamon-Fava S, Fava M, Rogers JT (2018) S-Adenosyl methionine and transmethylation pathways in neuropsychiatric diseases throughout life. Neurotherapeutics 15(1):156–175. https://doi.org/10.1007/s13311-017-0593-0
Brinkman AB, Nik-Zainal S, Simmer F, Rodríguez-González FG, Smid M, Alexandrov LB, Stunnenberg HG (2019) Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. Nat Commun 10(1):1–10. https://doi.org/10.1038/s41467-019-09828-0
Pfeifer GP (2018) Defining driver DNA methylation changes in human cancer. Int J Mol Sci 19(4):1166. https://doi.org/10.1016/B978-0-323-35955-9.00022-2
Bansal A, Pinney SE (2017) DNA methylation and its role in the pathogenesis of diabetes. Pediatr Diabetes 18(3):167–177
Grunseich C, Wang IX, Watts JA, Burdick JT, Guber RD, Zhu Z, Cheung VG (2018) Senataxin mutation reveals how R-loops promote transcription by blocking DNA methylation at gene promoters. Mol Cell 69(3):426–437. https://doi.org/10.1016/j.molcel.2017.12.030
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Ding W (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71
Uchida T, Wang C, Sato T, Gao J, Takashima R, Irie A, Koshiba K (1999) BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer. Int J Cancer 84(1):19–23. https://doi.org/10.1002/(SICI)1097-0215(19990219)84:1%3c19::AID-IJC4%3e3.0.CO;2-S
Arason A, Agnarsson BA, Johannesdottir G, Johannsson OT, Hilmarsdottir B, Reynisdottir I, Barkardottir RB (2019) The BRCA1 c. 4096+ 3A> G variant displays classical characteristics of pathogenic BRCA1 mutations in hereditary breast and ovarian cancers, but Still allows homozygous viability. Genes 10(11):882. https://doi.org/10.3390/genes10110882
Saiki RK, Bugawan TL, Horn GT, Mullis KB, Erlich HA (1986) Analysis of enzymatically amplified β-globin and HLA-DQα DNA with allele-specific oligonucleotide probes. Nature 324(6093):163–166. https://doi.org/10.1038/324163a0
Yi S, Long F, Cheng J, Huang D (2017) An optimized rapid bisulfite conversion method with high recovery of cell-free DNA. BMC Mol Biol 18(1):1–8. https://doi.org/10.1186/s12867-017-0101-4
Llinas-Arias P, Esteller M (2017) Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update. Open Biol 7(9):170152
Kedhari Sundaram M, Hussain A, Haque S, Raina R, Afroze N (2019) Quercetin modifies 5′ CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells. J Cell Biochem 120(10):18357–18369
Greenstein JP (2016) Biochemistry of cancer. Elsevier, Amsterdam
Bai X, Fu Y, Xue H, Guo K, Song Z, Yu Z, We M (2014) BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases. Oncol Lett 7(4):1088–1096
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. cell 100(1):57–70
Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345
Ruscito I, Gasparri ML, De Marco MP, Costanzi F, Besharat AR, Papadia A, Caserta D (2021) The clinical and pathological profile of BRCA1 gene methylated breast cancer women: a meta-analysis. Cancers 13(6):1391
Rojas-Jiménez E, Mejía-Gómez JC, Díaz-Velásquez C, Quezada-Urban R, Martínez Gregorio H, Vallejo-Lecuona F, Vaca-Paniagua F (2020) Comprehensive genomic profile of heterogeneous long follow-up triple-negative breast cancer and its clinical characteristics shows dna repair deficiency has better prognostic. Genes 11(11):1367
Harahap WA, Sudji IR, Nindrea RD (2018) BRCA1 promoter methylation and clinicopathological characteristics in sporadic breast cancer patients in Indonesia. Asian Pacific journal of cancer prevention: APJCP 19(9):2643
Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL (2005) BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 91(2):179–186
Yu J, Zayas J, Qin B, Wang L (2019) Targeting DNA methylation for treating triple-negative breast cancer. Pharmacogenomics 20(16):1151–1157
Shilpa V, Bhagat R, Premalata CS, Pallavi VR, Ramesh G, Krishnamoorthy L (2014) BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma—an Indian study. Tumor Biol 35(5):4277–4284
Moran S, Martinez-Cardús A, Boussios S, Esteller M (2017) Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol 14(11):682
Acknowledgements
We would like first to express our gratitude to Hassan II University for the provided financial support of this work, we are also grateful to the biopsies donors and physicians and contributors to this study. Our gratitude goes also to the members of the team of virology, oncology, medical and laboratory of virology microbiology quality biotechnologies / ecotoxicology biodiversity at the Faculty of Sciences and Technics-Mohammedia, University Hassan II of Casablanca, the CNRST—Rabat and the Ministry of Higher Education of the kingdom of Morocco for their support for this research.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
Supervision-MME, AB, MB, MEK; Materials- MME; Data collection&/or processing-MME, AB, MB, MEK; Analysis and or interpretation-MME; literature search-MME; writing-MME.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The study was approved by the Biomedical Research Ethics Committee of the School of Medicine and Pharmacy of Casablanca.
Consent to participate
All patients consented to participate in the study according to the ethical standards.
Consent for publication
All authors approved and consented to publish the presented results.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Saif, I., Bouziyane, A., Benhessou, M. et al. Detection of hypermethylation BRCA1/2 gene promoter in breast tumours among Moroccan women. Mol Biol Rep 48, 7147–7152 (2021). https://doi.org/10.1007/s11033-021-06705-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-021-06705-2